Home  >  Products  >  LGI1 (leucine-rich, glioma inactivated 1 ) Blocking Peptide (the N terminal of LGI1)(100ug)
LGI1 (leucine-rich, glioma inactivated 1 ) Blocking Peptide (the N terminal of LGI1)(100ug)

LGI1 (leucine-rich, glioma inactivated 1 ) Blocking Peptide (the N terminal of LGI1)(100ug)

Supplier: Aviva Systems Biology Incorporated
Star_fadedStar_fadedStar_fadedStar_fadedStar_faded
0 reviews | Write a Review Pencil
This is a synthetic peptide designed for use in combination with anti-LGI1 Antibody (ARP61478_P050), made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.
Reactivities: Human
Presku: AAP61478
Size: 100ug
Weight: 61kDa
Gene: The peptide is characterized by mass spectroscopy
Format: Lyophilized powder
Target: This gene is rearranged as a result of translocations in glioblastoma cell lines. The protein contains a hydrophobic segment representing a putative transmembrane domain with the amino terminus located outside the cell. It also contains leucine-rich repeats with conserved cysteine-rich flanking sequences. This gene is predominantly expressed in neural tissues and its expression is reduced in low grade brain tumors and significantly reduced or absent in malignant gliomas. Mutations in this gene result in autosomal dominant lateral temporal epilepsy.
Alternative names: EPITEMPIN; EPT; ETL1; IB1099
See Full Product Listings >